Trials keep scaling while approvals keep coming
The cure stack is still widening: 21,272 active trials now sit beneath a week of fresh regulatory and research movement. In the last 24 hours, 35 new cure research items and 38 new wire signals arrived, while the clinic kept advancing with FDA approval for LEQEMBI IQLIK initiation in Alzheimer’s and traditional approval for Fabhalta in primary IgA nephropathy. Otsuka is also preparing pivotal two-year phase 3 VISIONARY data for VOYXACT in IgAN, and the first UK patient has received a novel gene therapy for a rare cause of vision loss. The pattern is not a breakthrough headline but something more durable: disease programs are moving from promise to procedure, and the window is still open.
Global active cure-related trials total 21,272, with 35 new cure research items and 38 new wire signals added in the last 24 hours.
FDA action in Alzheimer’s and IgA nephropathy shows that therapies are still converting into access, while gene therapy and late-stage renal data suggest more diseases are moving toward real-world treatment.
Watch the forthcoming VISIONARY two-year data, and watch whether recent approvals translate into broader adoption fast enough to matter; momentum is building, but time remains the constraint.